Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Ionis Pharmaceuticals Inc shares valued at $60,687 were sold by Diaz Allene M. on Aug 22 ’25. At $42.53 per share, Diaz Allene M. sold 1,427 shares. The insider’s holdings dropped to 18,368 shares worth approximately $0.79 million following the completion of this transaction.
Also, BENNETT C FRANK sold 10,000 shares, netting a total of over 439,776 in proceeds. Following the sale of shares at $43.98 each, the insider now holds 93,466 shares.
Before that, BENNETT C FRANK had added 16,000 shares to its account. In a trade valued at $703,642, the Officer bought Ionis Pharmaceuticals Inc shares for $43.98 each.
As published in a research note from Morgan Stanley on July 31, 2025, Ionis Pharmaceuticals Inc [IONS] has been rated up from an Equal-weight to an Overweight and the price target has been revised to $62. Analysts at Barclays upgraded the stock from ‘”an Equal weight”‘ to ‘”an Overweight”‘ outlook in a report released in early July. As of April 07, 2025, H.C. Wainwright has initiated its “Buy” rating for IONS. Earlier on March 31, 2025, Redburn Atlantic initiated its rating. Their recommendation was “a Neutral” for IONS stock.
Analyzing IONS Stock Performance
On last trading session, Ionis Pharmaceuticals Inc [NASDAQ: IONS] rose 1.38% to $42.75. The stock’s lowest price that day was $41.945, but it reached a high of $43.07 in the same session. During the last five days, there has been a drop of approximately -0.14%. Over the course of the year, Ionis Pharmaceuticals Inc shares have dropped approximately -8.89%. Shares of the company reached a 52-week high of $45.66 on 07/30/25 and a 52-week low of $23.95 on 04/09/25.
Support And Resistance Levels for Ionis Pharmaceuticals Inc (IONS)
According to the 24-hour chart, there is a support level at 42.10, which, if violated, would cause prices to drop to 41.45. In the upper region, resistance lies at 43.24. The next price resistance is at 43.74. RSI (Relative Strength Index) is 53.57 on the 14-day chart, showing neutral technical sentiment.
Is Ionis Pharmaceuticals Inc subject to short interest?
Stocks of Ionis Pharmaceuticals Inc saw a sharp steep in short interest on 2025-08-15 dropping by -2.1 million shares to 10.79 million. Data from Yahoo Finance shows that the short interest on 2025-07-15 was 12.89 million shares. A decline of -19.51% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 5.47 of the overall float, the days-to-cover ratio (short ratio) decline to 5.47.
Which companies own the most shares of Ionis Pharmaceuticals Inc (IONS)?
In terms of Ionis Pharmaceuticals Inc share price expectations, FactSet research, analysts set an average price target of 62 in the next 12 months, up nearly 47.02% from the previous closing price of $42.17. Analysts anticipate Ionis Pharmaceuticals Inc stock to reach 82 by 2025, with the lowest price target being 43. In spite of this, 14 analysts ranked Ionis Pharmaceuticals Inc stock as Buy at the end of 2025. On August 02, 2024, BMO Capital Markets assigned a price target of “a Market perform” to the stock and downgraded coverage with a $60.
